Edition:
United States

Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

7.70USD
9 Dec 2016
Change (% chg)

$0.35 (+4.76%)
Prev Close
$7.35
Open
$7.40
Day's High
$8.00
Day's Low
$7.35
Volume
1,184,449
Avg. Vol
1,665,988
52-wk High
$32.31
52-wk Low
$5.70

Select another date:

Fri, Nov 4 2016

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

The effectiveness of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.

UPDATE 2-U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Nov 4 The effectiveness of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Nov 4 The effectiveness of Cempra Inc's experimental antibiotic to treat community acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration concluded on Friday.

BRIEF-Cempra stock trading halted today FDA advisory committee to discuss Solithromycin

* Cempra stock trading halted today; FDA advisory committee to discuss solithromycin

FDA highlights liver safety issues in Cempra drug review

Cempra Inc's experimental drug to treat community-acquired pneumonia, the kind recently suffered by presidential candidate Hillary Clinton, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

UPDATE 1-U.S. FDA highlights liver safety issues in Cempra drug review

Nov 2 Cempra Inc's experimental drug to treat community-acquired pneumonia, the kind recently suffered by presidential candidate Hillary Clinton, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

U.S. FDA highlights liver safety issues in Cempra drug review

Nov 2 Cempra Inc's experimental drug to treat community acquired pneumonia, the kind suffered by presidential candidate Hillary Clinton recently, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

BRIEF-Cempra receives $10 mln milestone payment from Toyama Chemical

* Cempra receives $10 million milestone payment from Toyama Chemical (a subsidiary of fujifilm holdings corporation) as solithromycin progresses to phase 3 studies in Japan Source text for Eikon: Further company coverage:

BRIEF-Cempra reports Q3 2016 results and provides corporate update

* Cempra reports third quarter 2016 financial results and provides corporate update

BRIEF-Cempra - EMA's CHMP will begin their assessment of Solithromycin

* Cempra announces European medicines agency validates MAA for solithromycin for treatment of CABP

Select another date: